Ya the signs are all there...
"Increased interest of the large pharmaceutical companies in acquisition of pipeline at each stage in the development and trials process has generated a very active market for early stage compounds that have shown promise in bench and animal tests. Treatment of cancer by non-toxic methods of inhibiting the action of PKCalpha has become an area of specific interest. We believe that PharmaGap has established a novel method for selection and inhibition of PKCalpha which matches well with the focus of research in a number of potential licensees or purchasers," Mr. McInnis said.
